fluorodeoxyglucose f18 has been researched along with Glycogen Storage Disease Type II in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Claeys, KG; Demaerel, P; Depuydt, CE; Sunaert, S; Van Laere, K | 1 |
| Plöckinger, U; Poellinger, A; Prasad, V; Tiling, N; Ziagaki, A | 1 |
2 other study(ies) available for fluorodeoxyglucose f18 and Glycogen Storage Disease Type II
| Article | Year |
|---|---|
White matter brain lesions in infantile-onset Pompe disease are not metabolically active using
Topics: Brain; Female; Fluorodeoxyglucose F18; Glycogen Storage Disease Type II; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Positron-Emission Tomography; White Matter | 2020 |
2-deoxy-2-[18]fluoro-D-glucose PET/CT (18FDG PET/CT) may not be a viable biomarker in Pompe disease.
Topics: Adult; Biomarkers; Contrast Media; Enzyme Replacement Therapy; Fluorodeoxyglucose F18; Glucose; Glycogen Storage Disease Type II; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Muscle, Skeletal; Positron Emission Tomography Computed Tomography | 2018 |